Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $45.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 56.36% from the company’s previous close.

A number of other research firms also recently issued reports on URGN. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Oppenheimer raised their price target on Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. D. Boral Capital reissued a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. Finally, Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma has an average rating of “Moderate Buy” and a consensus target price of $36.67.

Urogen Pharma Stock Performance

Shares of URGN opened at $28.78 on Monday. The business’s fifty day simple moving average is $21.76 and its two-hundred day simple moving average is $22.06. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $32.37. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -10.47 and a beta of 1.58.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million. As a group, research analysts forecast that Urogen Pharma will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. CWM LLC lifted its position in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after purchasing an additional 650 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after purchasing an additional 1,653 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after purchasing an additional 1,968 shares in the last quarter. Finally, Barclays PLC lifted its position in Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after purchasing an additional 2,125 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.